Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Rog

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2024
Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre studyJoyutpal Das, Gagana Mallawaarachchi, Jack Grimshaw, et al.
Practical Neurology|February 22, 2023
Outpatient neurology diagnostic coding: a proposed scheme for standardised implementationFran Biggin, Jo Knight, Rejith Dayanandan, et al.
Multiple Sclerosis and Related Disorders|January 6, 2024
Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion studyDavid Rog, Wallace Brownlee, Francisco Javier Carod-Artal, et al.
Practical Neurology|July 8, 2022
Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelinesRuth Dobson, David Rog, Caroline Ovadia, et al.
Multiple Sclerosis and Related Disorders|May 7, 2024
Prevalence, treatment and correlates of depression in multiple sclerosisCarolyn A Young, Dawn Langdon, David Rog, et al.
Journal of the Neurological Sciences|May 15, 2021
Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacyCarolyn A Young, Roger Mills, David Rog, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 19, 2025
Impact of relative deprivation and ethnicity on the incidence rate of amyotrophic lateral sclerosisJames Alder, Chukwu Chukwuma, Tracey Farragher, et al.
Journal of the Neurological Sciences|February 17, 2025
Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectoriesCarolyn A Young, David Rog, Basil Sharrack, et al.
Multiple Sclerosis and Related Disorders|May 19, 2021
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapiesAfagh Garjani, Rodden M Middleton, Rachael Hunter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2023
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensusPriyanka Iyer, Kate Wiles, Azza Ismail, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2024
Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre studyJoyutpal Das, Gagana Mallawaarachchi, Jack Grimshaw, et al.
Practical Neurology|February 22, 2023
Outpatient neurology diagnostic coding: a proposed scheme for standardised implementationFran Biggin, Jo Knight, Rejith Dayanandan, et al.
Multiple Sclerosis and Related Disorders|January 6, 2024
Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion studyDavid Rog, Wallace Brownlee, Francisco Javier Carod-Artal, et al.
Practical Neurology|July 8, 2022
Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelinesRuth Dobson, David Rog, Caroline Ovadia, et al.
Multiple Sclerosis and Related Disorders|May 7, 2024
Prevalence, treatment and correlates of depression in multiple sclerosisCarolyn A Young, Dawn Langdon, David Rog, et al.
Journal of the Neurological Sciences|May 15, 2021
Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacyCarolyn A Young, Roger Mills, David Rog, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 19, 2025
Impact of relative deprivation and ethnicity on the incidence rate of amyotrophic lateral sclerosisJames Alder, Chukwu Chukwuma, Tracey Farragher, et al.
Journal of the Neurological Sciences|February 17, 2025
Clinical and socio-demographic characteristics of people with multiple sclerosis at the time of diagnosis: Influences on outcome trajectoriesCarolyn A Young, David Rog, Basil Sharrack, et al.
Multiple Sclerosis and Related Disorders|May 19, 2021
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapiesAfagh Garjani, Rodden M Middleton, Rachael Hunter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 6, 2023
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensusPriyanka Iyer, Kate Wiles, Azza Ismail, et al.
Pageof 5